Bharat Biotech Vaccine
Fair Pharma Scorecard
Applying human rights to pharma
Menu
Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Anhui Zhifei has not published a global access plan for its product.
Anhui Zhifei has not committed to comply with human rights.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
Anhui Zhifei has not committed to C-TAP or the MPP.
Anhui Zhifei has not committed to not enforcing the exclusive rights of Covid-19 related patents.
Anhui has not signed an agreement with the ACT Accelerator. The vaccine is now undergoing phase III clinical trials in Uzbekistan, and has not received WHO approval yet.
The vaccine has been approved for use in Uzbekistan, which participated in phase 3 clinical trials, and contributed to the development of the vaccine. Anhui Longcom is sharing the technology to allow Uzbekistan to produce it locally.Â
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]
Anhui Longcom has transferred the technology to produce the vaccine to Uzbekistan to allow it to produce it locally.Â
Anhui Longcom has promised to supply the vaccine to Uzbekistan at preferential prices, but there is no evidence of a differential pricing strategy based on a country’s ability to pay, and the cost of the vaccine has not been disclosed yet.
